Literature DB >> 15673754

Incidence and mechanism of ciprofloxacin resistance in Campylobacter spp. isolated from commercial poultry flocks in the United Kingdom before, during, and after fluoroquinolone treatment.

Deborah J Griggs1, Maggie M Johnson, Jennifer A Frost, Tom Humphrey, Frieda Jørgensen, Laura J V Piddock.   

Abstract

Five commercial broiler flocks were treated with a fluoroquinolone for a clinically relevant infection. Fresh feces from individual chickens and environmental samples were cultured for campylobacters before, during, and weekly posttreatment until slaughter. Both Campylobacter jejuni and C. coli were isolated during all treatment phases. An increased proportion of quinolone-resistant strains was seen during treatment, and these strains persisted posttreatment. One quinolone-resistant isolate of each species, each serotype, and each phage type from each sample at all treatment phases was examined for its phenotype and mechanism of resistance. Two resistant phenotypes were isolated: Nal(r) Cip(r) and Nal(r) Cip(s). The majority (269 of 290) of fluoroquinolone-resistant isolates, whether they were C. jejuni or C. coli, had a mutation in gyrA that resulted in the substitution Thr-86-->Ile. The other gyrA mutations detected were Thr-86-->Ala (n = 17) and Asp-90-->Asn (n = 10). The genotypic variation, based on the silent mutations in gyrA identified by the denaturing high-performance liquid chromatography pattern and DNA sequencing, was used to supplement typing data and provided evidence for both the spread of preexisting resistant strains and the selection of spontaneous resistant mutants in treated flocks. Multidrug resistance was significantly (P < 0.01) associated with resistance to ciprofloxacin. Twenty-five percent (73 of 290) of ciprofloxacin-resistant isolates but only 13% (24 of 179) of susceptible isolates were resistant to three or more unrelated antimicrobial agents. In conclusion, quinolone-resistant campylobacters were isolated from commercial chicken flocks in high numbers following therapy with a veterinary fluoroquinolone. Most ciprofloxacin-resistant isolates had the GyrA substitution Thr-86-->Ile. Resistant isolates were isolated from the feces of some flocks up to the point of slaughter, which may have consequences for public health.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673754      PMCID: PMC547197          DOI: 10.1128/AAC.49.2.699-707.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Characterization of high-level quinolone resistance in Campylobacter jejuni.

Authors:  T D Gootz; B A Martin
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  Detection of gyrA mutations in quinolone-resistant Salmonella enterica by denaturing high-performance liquid chromatography.

Authors:  Deborah J Eaves; Ernesto Liebana; Martin J Woodward; Laura J V Piddock
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences.

Authors:  J Parkhill; B W Wren; K Mungall; J M Ketley; C Churcher; D Basham; T Chillingworth; R M Davies; T Feltwell; S Holroyd; K Jagels; A V Karlyshev; S Moule; M J Pallen; C W Penn; M A Quail; M A Rajandream; K M Rutherford; A H van Vliet; S Whitehead; B G Barrell
Journal:  Nature       Date:  2000-02-10       Impact factor: 49.962

4.  Characterization of gyrA mutations associated with fluoroquinolone resistance in Campylobacter coli by DNA sequence analysis and MAMA PCR.

Authors:  G Zirnstein; L Helsel; Y Li; B Swaminathan; J Besser
Journal:  FEMS Microbiol Lett       Date:  2000-09-01       Impact factor: 2.742

5.  Phage typing of Campylobacter jejuni and Campylobacter coli and its use as an adjunct to serotyping.

Authors:  J A Frost; J M Kramer; S A Gillanders
Journal:  Epidemiol Infect       Date:  1999-08       Impact factor: 2.451

6.  Specific PCR identification and differentiation of the thermophilic campylobacters, Campylobacter jejuni, C. coli, C. lari, and C. upsaliensis.

Authors:  C Fermér; E O Engvall
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

7.  Use of a LightCycler gyrA mutation assay for identification of ciprofloxacin-resistant Campylobacter coli.

Authors:  Alessandra Carattoli; Anna Dionisi; Ida Luzzi
Journal:  FEMS Microbiol Lett       Date:  2002-08-27       Impact factor: 2.742

8.  Expression of the efflux pump genes cmeB, cmeF and the porin gene porA in multiple-antibiotic-resistant Campylobacter jejuni.

Authors:  Lilian Pumbwe; Luke P Randall; Martin J Woodward; Laura J V Piddock
Journal:  J Antimicrob Chemother       Date:  2004-06-16       Impact factor: 5.790

9.  Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations.

Authors:  Y Wang; W M Huang; D E Taylor
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  CmeABC functions as a multidrug efflux system in Campylobacter jejuni.

Authors:  Jun Lin; Linda Overbye Michel; Qijing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

View more
  24 in total

1.  Risk factors for ciprofloxacin resistance in reported Campylobacter infections in southern Alberta.

Authors:  J Y M Johnson; L M McMullen; P Hasselback; M Louie; G Jhangri; L D Saunders
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

2.  Campylobacter coli in swine production: antimicrobial resistance mechanisms and molecular epidemiology.

Authors:  Siddhartha Thakur; Wondwossen A Gebreyes
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

3.  Prevalence and subtypes of ciprofloxacin-resistant Campylobacter spp. in commercial poultry flocks before, during, and after treatment with fluoroquinolones.

Authors:  Tom J Humphrey; Frieda Jørgensen; Jennifer A Frost; Haddy Wadda; Gil Domingue; Nicola C Elviss; Deborah J Griggs; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  Effect of macrolide usage on emergence of erythromycin-resistant Campylobacter isolates in chickens.

Authors:  Jun Lin; Meiguan Yan; Orhan Sahin; Sonia Pereira; Yun-Juan Chang; Qijing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

5.  Antimicrobial Resistance in Campylobacter coli and Campylobacter jejuni from Human Campylobacteriosis in Taiwan, 2016 to 2019.

Authors:  Ying-Shu Liao; Bo-Han Chen; Ru-Hsiou Teng; You-Wun Wang; Jui-Hsien Chang; Shiu-Yun Liang; Chi-Sen Tsao; Yu-Ping Hong; Hui-Yung Sung; Chien-Shun Chiou
Journal:  Antimicrob Agents Chemother       Date:  2021-11-08       Impact factor: 5.938

6.  Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.

Authors:  Deborah J Griggs; Leanne Peake; Margaret M Johnson; Saba Ghori; A Mott; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

Review 7.  Antibiotic resistance in Campylobacter: emergence, transmission and persistence.

Authors:  Taradon Luangtongkum; Byeonghwa Jeon; Jing Han; Paul Plummer; Catherine M Logue; Qijing Zhang
Journal:  Future Microbiol       Date:  2009-03       Impact factor: 3.165

8.  Fluoroquinolone use in food animals.

Authors:  Peter Collignon
Journal:  Emerg Infect Dis       Date:  2005-11       Impact factor: 6.883

Review 9.  Antimicrobial drug use in food-producing animals and associated human health risks: what, and how strong, is the evidence?

Authors:  Karin Hoelzer; Nora Wong; Joe Thomas; Kathy Talkington; Elizabeth Jungman; Allan Coukell
Journal:  BMC Vet Res       Date:  2017-07-04       Impact factor: 2.741

10.  Key role of Mfd in the development of fluoroquinolone resistance in Campylobacter jejuni.

Authors:  Jing Han; Orhan Sahin; Yi-Wen Barton; Qijing Zhang
Journal:  PLoS Pathog       Date:  2008-06-06       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.